Association between apolipoprotein E4 and cognitive decline in elderly adults

Journal of the American Geriatrics Society

Volumn 55, Issue 11, 2007, Pages 1777-1785

  Packard, Chris J ^a,f   Westendorp, Rudi G J ^b   Stott, David J ^a   Caslake, Muriel J ^a   Murray, Heather M ^a   Shepherd, James ^d   Blauw, Gerard J ^b   Murphy, Michael B ^d   Bollen, Edward L E M ^b   Buckley, Brendan M ^d   Cobbe, Stuart M ^a   Ford, Ian ^a   Gaw, Allan ^e   Hyland, Michael ^d   Jukema, J Wouter ^b   Kamper, Adriaan M ^b   Macfarlane, Peter W ^a   Jolles, Jellemer ^c   Perry, Ivan J ^d   Sweeney, Brian J ^d   Twomey, Cillian ^d   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d University College Cork and INFANT Centre   (Ireland)

^e NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Dementia; Memory; Statin; Trial

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; NETHERLANDS; PROSPECTIVE STUDY; UNITED KINGDOM; WORD RECOGNITION; ALZHEIMER DISEASE; BLOOD; CLASSIFICATION; CROSS-SECTIONAL STUDY; GENETICS; HETEROZYGOTE DETECTION; MENTAL HEALTH; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; PHENOTYPE; RISK FACTOR; STATISTICS;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN E4; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEMENTIA, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; IRELAND; MALE; MENTAL STATUS SCHEDULE; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; PRAVASTATIN; RISK FACTORS; SCOTLAND; STATISTICS AS TOPIC; TRIGLYCERIDES;

EID: 35748971011     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01415.x     Document Type: Article

References (50)

1. Dik MG, Deeg DJ, Bouter LM et al. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: A population-based study. Stroke 2000 31 : 2431 2436.
2. Haan MN, Shemanski L, Jagust WJ et al. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999 282 : 40 46.
3. Launer LJ, Ross GW, Petrovitch H et al. Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 2000 21 : 49 55.
4. Ott A, Stolk RP, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999 53 : 1937 1942.
5. Podewils LJ, Guallar E, Kuller LH et al. Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005 161 : 639 651.
6. Geda YE, Knopman DS, Mrazek DA et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: A prospective cohort study. Arch Neurol 2006 63 : 435 440.
7. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993 43 : 1467 1472.
8. Smith JD. Apolipoproteins and aging: Emerging mechanisms. Ageing Res Rev 2002 1 : 345 365.
9. Mahley RW, Huang Y. Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999 10 : 207 217.
10. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997 278 : 1349 1356.
11. Small BJ, Rosnick CB, Fratiglioni L et al. Apolipoprotein E and cognitive performance: A meta-analysis. Psychol Aging 2004 19 : 592 600.
12. Wilson RS, Schneider JA, Barnes LL et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002 59 : 1154 1160.
13. Bunce D, Fratiglioni L, Small BJ et al. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology 2004 63 : 816 821.
14. Small BJ, Graves AB, McEvoy CL et al. Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology 2000 54 : 2082 2088.
15. Reynolds CA, Prince JA, Feuk L et al. Longitudinal memory performance during normal aging: Twin association models of APOE and other Alzheimer candidate genes. Behav Genet 2006 36 : 185 194.
16. Swan GE, Lessov-Schlaggar CN, Carmelli D et al. Apolipoprotein E epsilon4 and change in cognitive functioning in community-dwelling older adults. J Geriatr Psychiatry Neurol 2005 18 : 196 201.
17. Deary IJ, Whiteman MC, Pattie A et al. Apolipoprotein E gene variability and cognitive functions at age 79: A follow-up of the Scottish mental survey of 1932. Psychol Aging 2004 19 : 367 371.
18. Hofer SM, Christensen H, MacKinnon AJ et al. Change in cognitive functioning associated with apoE genotype in a community sample of older adults. Psychol Aging 2002 17 : 194 208.
19. Reitz C, Luchsinger JA, Tang MX et al. Stroke and memory performance in elderly persons without dementia. Arch Neurol 2006 63 : 571 576.
20. Qiu C, Winblad B, Fratiglioni L. Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. Neurol Res 2006 28 : 650 656.
21. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006 66 : S79 S85.
22. Persson J, Lind J, Larsson A et al. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: A risk for AD? Neurology 2006 66 : 1029 1033.
23. van Exel E, de Craen AJ, Gussekloo J et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002 51 : 716 721.
24. Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001 322 : 1447 1451.
25. Wieringa GE, Burlinson S, Rafferty JA et al. Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia. Int J Geriatr Psychiatry 1997 12 : 359 362.
26. Li G, Shofer JB, Kukull WA et al. Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. Neurology 2005 65 : 1045 1050.
27. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002 360 : 1623 1630.
28. Houx PJ, Shepherd J, Blauw GJ et al. Testing cognitive function in elderly populations: The prosper study. Prospective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 2002 73 : 385 389.
29. Kalmijn S, Feskens EJ, Launer LJ et al. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996 27 : 2230 2235.
30. Kalmijn S, Foley D, White L et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol 2000 20 : 2255 2260.
31. O'Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurol 2003 2 : 89 98.
32. Shepherd J, Blauw GJ, Murphy MB et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999 84 : 1192 1197.
33. The lipid research clinics program epidemiology committee. Plasma lipid distributions in selected North American populations: The lipid research clinics program prevalence study. Circulation 1979 60 : 427 439.
34. Havekes LM, de Knijff P, Beisiegel U et al. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987 28 : 455 463.
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
36. Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985 112 : 201 210.
37. Houx PJ, Jolles J, Vreeling FW. Stroop interference: Aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993 19 : 209 224.
38. Hobart JC, Lamping DL, Freeman JA et al. Evidence-based measurement: Which disability scale for neurologic rehabilitation? Neurology 2001 57 : 639 644.
39. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J 1965 14 : 61 65.
40. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969 9 : 179 186.
41. Wolf PA, D'Agostino RB, Belanger AJ et al. Probability of stroke: A risk profile from the Framingham Study. Stroke 1991 22 : 312 318.
42. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002 360 : 1623 1630.
43. Weisgraber KH, Mahley RW. Human apolipoprotein E: The Alzheimer's disease connection. FASEB J 1996 10 : 1485 1494.
44. Dik MG, Jonker C, Comijs HC et al. Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001 57 : 2217 2222.
45. Yip AG, Brayne C, Easton D et al. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J Med Genet 2002 39 : 639 643.
46. Wilson RS, Schneider JA, Barnes LL et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002 59 : 1154 1160.
47. Bretsky P, Guralnik JM, Launer L et al. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 2003 60 : 1077 1081.
48. O'Brien JT. Vascular cognitive impairment. Am J Geriatr Psychiatry 2006 14 : 724 33.
49. Oosterman JM, Scherder EJ. Distinguishing between vascular dementia and Alzheimer's disease by means of the WAIS: A meta-analysis. J Clin Exp Neuropsychol 2006 28 : 1158 1175.
50. Poore QE, Rapport LJ, Fuerst DR et al. Word list generation performance in Alzheimer's disease and vascular dementia. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2006 13 : 86 94.